Maravai LifeSciences (NASDAQ:MRVI) Issues Quarterly Earnings Results

Maravai LifeSciences (NASDAQ:MRVI) posted its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03, FiscalAI reports. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $45.85 million for the quarter, compared to analysts’ expectations of $43.56 million.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• Q3 revenue rose 10% to $45.9 million, led by mRNA growth of 28% (GMP consumables +30%, discovery mRNA +27%). Cygnus grew 8%, marking its sixth consecutive quarter of year-over-year growth.
• Adjusted EBITDA improved by $16.6 million year over year to $5.8 million, and Maravai raised its 2026 revenue outlook to $212–$216 million and adjusted EBITDA outlook to $40–$42 million.
• Management cited a healthy mRNA pipeline and growing customer adoption: 10 discovery customers transitioned to clinical-stage GMP year to date, surpassing the company’s target of nine, and more than 180 customers are using ModTail.
• Management cautioned that GMP and CDMO orders are program-driven and can vary significantly by quarter; it expects GMP activity to skew toward the second half of 2027 and does not anticipate substantial 2027 GMP revenue from ModTail. Specialty chemistry revenue also declined 4% as large prior-year orders did not repeat.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock traded up $0.27 during trading on Wednesday, reaching $7.71. The company’s stock had a trading volume of 3,624,037 shares, compared to its average volume of 2,400,230. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -14.84 and a beta of 0.61. Maravai LifeSciences has a one year low of $2.55 and a one year high of $9.42. The business’s fifty day moving average price is $7.42 and its 200-day moving average price is $5.29. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wall Street Zen cut Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. TD Cowen began coverage on Maravai LifeSciences in a report on Monday, October 5th. They set a “buy” rating and a $9.00 price objective for the company. Wells Fargo & Company boosted their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. Finally, UBS Group raised their price target on Maravai LifeSciences from $2.50 to $8.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.38.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.